BioLineRx Valuation

Is YP2A undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of YP2A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: YP2A (€0.22) is trading below our estimate of fair value (€5.08)

Significantly Below Fair Value: YP2A is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for YP2A?

Key metric: As YP2A is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for YP2A. This is calculated by dividing YP2A's market cap by their current revenue.
What is YP2A's PS Ratio?
PS Ratio	1.4x
Sales	US$17.05m
Market Cap	US$24.69m

YP2A key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.9x
Enterprise Value/EBITDA	-0.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does YP2A's PS Ratio compare to its peers?

The above table shows the PS ratio for YP2A vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	6x
2INV 2invest	8.1x	n/a	€62.7m
HPHA Heidelberg Pharma	12x	16.6%	€102.1m
MDG1 Medigene	3x	16.1%	€22.5m
CNW co.don	0.7x	n/a	€6.5m
YP2A BioLineRx	1.4x	27.8%	€90.0m

Price-To-Sales vs Peers: YP2A is good value based on its Price-To-Sales Ratio (1.4x) compared to the peer average (7.7x).

Price to Sales Ratio vs Industry

How does YP2A's PS Ratio compare vs other companies in the DE Biotechs Industry?

7 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	8.0x	21.8%
YP2A BioLineRx	1.4x	27.8%	US$24.69m
CNW co.don	0.7x	n/a	US$6.97m
V9Z Aceragen	0.4x	n/a	US$3.12m

7 Companies		Estimated Growth	Market Cap
Industry Avg.	8.0x	42.4%
YP2A BioLineRx	1.4x	34.4%	US$24.69m

No more companies

Price-To-Sales vs Industry: YP2A is good value based on its Price-To-Sales Ratio (1.4x) compared to the European Biotechs industry average (8.1x).

Price to Sales Ratio vs Fair Ratio

What is YP2A's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

YP2A PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.4x
Fair PS Ratio	2.5x

Price-To-Sales vs Fair Ratio: YP2A is good value based on its Price-To-Sales Ratio (1.4x) compared to the estimated Fair Price-To-Sales Ratio (2.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Aspen Pharmacare Holdings

R74.3b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R9.00

0.6%

5.3%

Pharming Group

€492.8m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.71

0.4%

-33.2%

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z

€8.45

1.1%

2.9%